355 related articles for article (PubMed ID: 35294720)
1. Determinants and Effectiveness of BNT162b2 mRNA Vaccination Among Patients with Atopic Dermatitis: A Population-Based Study.
Kridin K; Schonmann Y; Onn E; Bitan DT; Weinstein O; Cohen AD
Am J Clin Dermatol; 2022 May; 23(3):385-392. PubMed ID: 35294720
[TBL] [Abstract][Full Text] [Related]
2. Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study.
Xiong X; Wong CKH; Au ICH; Lai FTT; Li X; Wan EYF; Chui CSL; Chan EWY; Cheng FWT; Lau KTK; Lee CH; Woo YC; Lui DTW; Wong ICK
Thyroid; 2022 May; 32(5):505-514. PubMed ID: 35216517
[No Abstract] [Full Text] [Related]
3. Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study.
Chemaitelly H; Ayoub HH; AlMukdad S; Coyle P; Tang P; Yassine HM; Al-Khatib HA; Smatti MK; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
Lancet Microbe; 2022 Dec; 3(12):e944-e955. PubMed ID: 36375482
[TBL] [Abstract][Full Text] [Related]
4. Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes.
Lin DY; Gu Y; Xu Y; Wheeler B; Young H; Sunny SK; Moore Z; Zeng D
JAMA; 2022 Oct; 328(14):1415-1426. PubMed ID: 36155617
[TBL] [Abstract][Full Text] [Related]
5. The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study.
Gazit S; Shlezinger R; Perez G; Lotan R; Peretz A; Ben-Tov A; Herzel E; Alapi H; Cohen D; Muhsen K; Chodick G; Patalon T
Ann Intern Med; 2022 May; 175(5):674-681. PubMed ID: 35157493
[TBL] [Abstract][Full Text] [Related]
6. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines.
Brunner-Ziegler S; Spath T; Kornek G; König F; Parschalk B; Schnetzinger M; Straßl RP; Savic R; Foit A; Resch H; Thalhammer F
Clin Microbiol Infect; 2022 Apr; 28(4):596-601. PubMed ID: 34915073
[TBL] [Abstract][Full Text] [Related]
7. Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19-Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021.
Muhsen K; Maimon N; Mizrahi AY; Varticovschi B; Bodenheimer O; Cohen D; Dagan R
JAMA Netw Open; 2022 Jul; 5(7):e2219940. PubMed ID: 35796153
[TBL] [Abstract][Full Text] [Related]
8. Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: A population-based cohort study.
Xiong X; Lui DTW; Chung MSH; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Cheng FWT; Cheung CL; Chan EWY; Lee CH; Woo YC; Tan KCB; Wong CKH; Wong ICK
PLoS Med; 2023 Jul; 20(7):e1004274. PubMed ID: 37486927
[TBL] [Abstract][Full Text] [Related]
9. Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization.
Wong CKH; Xiong X; Lau KTK; Chui CSL; Lai FTT; Li X; Chan EWY; Wan EYF; Au ICH; Cowling BJ; Lee CK; Wong ICK
BMC Med; 2022 Mar; 20(1):119. PubMed ID: 35296305
[TBL] [Abstract][Full Text] [Related]
10. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study.
Muhsen K; Maimon N; Mizrahi A; Bodenheimer O; Cohen D; Maimon M; Grotto I; Dagan R
Clin Infect Dis; 2022 Aug; 75(1):e755-e763. PubMed ID: 34698808
[TBL] [Abstract][Full Text] [Related]
12. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women.
Goldshtein I; Nevo D; Steinberg DM; Rotem RS; Gorfine M; Chodick G; Segal Y
JAMA; 2021 Aug; 326(8):728-735. PubMed ID: 34251417
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of mRNA BNT162b2 COVID-19 vaccine against SARS-CoV-2 Delta variant among elderly residents from a long-term care facility, South of France, May 2021.
Sánchez Ruiz MA; Adonias G; Robaglia-Schlupp A; Rapilly F; Chabert M; Ramalli L; Reilhes O; Bruel C; Malfait P; Chaud P
Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2586-2591. PubMed ID: 35442474
[TBL] [Abstract][Full Text] [Related]
14. Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI).
Katz MA; Harlev EB; Chazan B; Chowers M; Greenberg D; Peretz A; Tshori S; Levy J; Yacobi M; Hirsch A; Amichay D; Weinberger R; Dor AB; Taraday EK; Reznik D; Chayat CB; Sagas D; Zvi HB; Berdinstein R; Rashid G; Avni YS; Mandelboim M; Zuckerman N; Rainy N; Akriv A; Dagan N; Kepten E; Barda N; Balicer RD
Vaccine; 2022 Jan; 40(3):512-520. PubMed ID: 34903372
[TBL] [Abstract][Full Text] [Related]
15. The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data.
Chodick G; Tene L; Rotem RS; Patalon T; Gazit S; Ben-Tov A; Weil C; Goldshtein I; Twig G; Cohen D; Muhsen K
Clin Infect Dis; 2022 Feb; 74(3):472-478. PubMed ID: 33999127
[TBL] [Abstract][Full Text] [Related]
16. Iron deficiency and the effectiveness of the BNT162b2 vaccine for SARS-CoV-2 infection: A retrospective, longitudinal analysis of real-world data.
Tene L; Karasik A; Chodick G; Pereira DIA; Schou H; Waechter S; Göhring UM; Drakesmith H
PLoS One; 2023; 18(5):e0285606. PubMed ID: 37216375
[TBL] [Abstract][Full Text] [Related]
17. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study.
Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Pályi B; Formanek-Balku E; Molnár GA; Herczeg R; Gyenesei A; Miseta A; Kollár L; Wittmann I; Müller C; Kásler M
Clin Microbiol Infect; 2022 Mar; 28(3):398-404. PubMed ID: 34838783
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19.
Hammerman A; Sergienko R; Friger M; Beckenstein T; Peretz A; Netzer D; Yaron S; Arbel R
N Engl J Med; 2022 Mar; 386(13):1221-1229. PubMed ID: 35172072
[TBL] [Abstract][Full Text] [Related]
19. Trends in COVID-19 Vaccine Administration and Effectiveness Through October 2021.
Winkelman TNA; Rai NK; Bodurtha PJ; Chamberlain AM; DeSilva M; Jeruzal J; Johnson SG; Kharbanda A; Klyn N; Mink PJ; Muscoplat M; Waring S; Yu Y; Drawz PE
JAMA Netw Open; 2022 Mar; 5(3):e225018. PubMed ID: 35357452
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness of mRNA vaccines to prevent SARS-CoV-2 infection and hospitalisation for COVID-19 according to the time elapsed since their administration in health professionals in the Valencian Autonomous Community (Spain).
Chico-Sánchez P; Gras-Valentí P; Algado-Sellés N; Jiménez-Sepúlveda N; Vanaclocha H; Peiró S; Burgos JS; Berenguer A; Navarro D; Sánchez-Payá J;
Prev Med; 2022 Oct; 163():107237. PubMed ID: 36057393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
